What is the effectiveness and safety of mirtazapine versus escitalopram in alleviating cancer-associated poly-symptomatology (the MIR-P study)? A mixed-method randomized controlled trial protocol

Guillaume Economos1,2*, Marine Alexandre3, Elise Perceau-Chambard2, Laurent Villeneuve3, Fabien Subtil3, Julie Haesebaert3† and Olivier Glehen4†

Abstract

Background: Advanced cancer patients often experience multiple symptoms at a same time. This might lead to polypharmacy and increase adverse events representing major threats to the quality of health care, especially in palliative care situations. Mirtazapine, an antidepressant agent, has been suggested as a potential relevant drug to alleviate multiple cancer-related symptoms at a same time.

Therefore, the present study aims to assess the effectiveness of mirtazapine in alleviating multiple symptoms at a same time in advanced cancer patients suffering from a major depressive episode compared to a group receiving escitalopram, another antidepressant agent.

Methods: Multicentre, prospective, randomized, controlled trial in 12 palliative care services in France. The study will be based on a mixed-method methodology using parallel groups, of oral mirtazapine compared with oral escitalopram, with a 56 day follow-up. The primary outcome will be an improvement of the Global health Status (issued from the EORTC-QLQ-C30) on day 56. 418 participants will be clinically followed-up on day 7 and 56 and will have a telephonic assessment on days 14 and 28. A sub-sample of participants will be invited to take part in semi-structured qualitative interviews at baseline and day 56. For the qualitative part, purposeful sampling will be used.

Discussion: This study will provide evidence for the pharmaceutics management of poly-symptomatology in advanced cancer patients. This could lead to important changes in the management of those patients by using a single molecule to alleviate multiple symptoms at a same time, potentially improving medication adherence, symptoms’ control, and reducing the risk of medications adverse events.

Trial registration: Trial registration: NCT04763135. Registered 18 March 2021.
Background

Despite continuous progress in cancer specific treatments, cancer remains the first leading cause of death in European countries. Therefore, the scientific community has an increasing interest in improving cancer patient’s quality of life [1, 2].

Cancer patients are highly burdened by symptoms with variability depending on cancer site, stage, disease trajectory, and cancer treatments [3, 4]. This burden worsens with the disease progression. For this reason, advanced cancer patients very often experience symptoms altering their quality of life, while the aim, at this stage, is to improve it. Indeed, more than half of advanced cancer patients experience fatigue, pain, lack of energy, tiredness or lack of appetite. Unfortunately, as patients often experience multiple symptoms at the same time, they might need multiple drugs, resulting in higher risk of adverse event or drug interactions [5, 6]. A potential solution to avoid such an issue might be to use a single drug to target multiple symptoms at the same time. Additionally, very few treatments are available for some symptoms, for instance, no treatment is currently licensed in Europe for breathlessness and a very few are available for lack of appetite or loss of weight.

Mirtazapine is a licensed anti-depressive treatment, advocated to be an eligible drug in treating multiple cancer related symptoms [7, 8]. Indeed, mirtazapine has an α-2 adrenergic activity which increases noradrenergic and serotonergic central neurotransmitters, leading to its short-term effect on acute depressive disorders [9]. Besides this α-2 adrenergic activity, mirtazapine also links to 5HT3 receptors and H1 receptors. This activity on various central and periphery receptors might have various effects on appetite, sleep disorders, pruritus, emesis, breathlessness and other multiple symptoms. Numerous recent studies gave additional clinical argument to support mirtazapine as an effective treatment for sleep disorders [10], breathlessness [11], and lack of appetite in advanced cancer patients [12].

Unfortunately, our previously published review highlighted that, despite encouraging results in various symptoms, evidence for the effectiveness of mirtazapine in improving quality of life in cancer patients experiencing poly-symptomatology is still lacking of robust randomized controlled trials [13].

Because health-related quality of life is a highly associated with the level of burden driven by symptoms; our research aims to assess the effectiveness of mirtazapine in improving health-related quality-of-life (HRQoL) in advanced cancer patients experiencing poly-symptomatology.

Hypothesis

We hypothesize that oral mirtazapine is superior to another antidepressant drug (oral escitalopram) in improving health-related quality of life of poly-symptomatic advanced cancer patients suffering from depression.

Objectives

The primary objective will be to assess the effectiveness of oral mirtazapine in improving HRQoL in poly-symptomatic advanced cancer patients suffering from depression after 56 days of treatment, compared with oral escitalopram.

The secondary objectives are:

i- To assess the effectiveness of oral mirtazapine in poly-symptomatic advanced cancer patients suffering from depression compared with escitalopram on the following outcomes:

- The experience of poly-symptomatology, poly-medication, and taking antidepressant agents and explore the dynamic of this experience between inclusion and 56 days.
- The improvement of the following symptom intensity: depressive mood, pain, nausea, lack of appetite, vomiting, breathlessness, sleep disorders and anxiety at 28 and 56 days.
- The improvement of the different functional capacities at 56 days.
- The mitigation of the loss of weight at 28 and 56 days.
- The use of medications to treat associated symptoms at 28 and 56 days.

ii- To assess the safety of oral mirtazapine in poly-symptomatic advanced cancer patients suffering from depression compared with escitalopram on the following outcomes:

- The experience of poly-symptomatology, poly-medication, and taking antidepressant agents.

iii- To assess the compliance to the treatments.

Methods

The trial will be a multicenter, prospective, randomized, open-labelled, controlled trial based on a mixed-method methodology using parallel groups, of oral mirtazapine (intervention) compared with oral...
escitalopram (control), with a 56-day follow-up. Semi-structures interviews will be performed on a purposive sample for qualitative outcomes. The 418 participants will be followed-up on day 7, 14, 28 and 56 for a 56-day period. A sub-group of participants will be invited to take part in qualitative interviews at baseline and day 56. Recruitment of participants for the qualitative part will be based on a purposive sampling. An overview of the study (Fig. 1) and an overview of the study events (Table 1) are provided below.

![Fig. 1 Overview of the study](image)

### Table 1: Overview of the study events for each participant during the follow-up period

| STEPS | Screening (J-14 à J-2) | Inclusion Randomisation | V2 Telephone call | V3 Telephone call | V4 Clinical assessment | V5 Clinical assessment |
|-------|------------------------|-------------------------|-------------------|-------------------|-----------------------|-----------------------|
| Time  | J0                     | J7 ± 1j                 | J14 ± 1j          | J28 ± 3j          | J56 ± 3j              |
| Actions |                        |                         |                    |                    |                       |                       |
| Inclusion and non-inclusion criteria | X | X | | | |
| ECG et postural hypotenstion test | | | | | |
| Study information delivery | X | X | | | |
| Informed consent | | | | | |
| MADRS | X | (X)³ | | | | |
| HADS-D | X | (X)³ | | | | |
| QLQ-C30 | | | | | | |
| ESAS12-F | | | | | | |
| ASEC | X | X | X | X | X | |
| Factor 1 of the MARS | | | | | | |
| Clinical assessment: weight, blood pressure, Performans Status | X | | | | |
| Treatment list | | | X | | |
| Sociodemographic data¹ | X | | | | |
| Randomisation | | | | | |
| Treatment doses adaptation | X | (X) | | | | |
| Adhesion to treatment assessment (pill count) | | | | | | |
| Semi-structured interviews | X | | | | | |
| Side effects | X | X | X | | |

¹ _Socio-demographics:_ date of birth, marital status, number of children, declared level of autonomy/dependence, professional position, way of life, kind of home support, cancer type, stage of the cancer, prior and current cancer treatments, personal background of psychotropic drugs use, the existence of a psychological or nutritional follow-up (and frequency of it)

² _HADS-D/MADRS:_ if not available at the time of screening or older than 7 days old

³ _Clinical assessment:_ might be performed using teleconsultation if needed
Population
Our study has interest in the population of adult patients suffering from an advanced cancer, who are diagnosed from a depressive syndrome and are experiencing at least another symptom.

Sample Size
Based on an expected standard deviation of 26 in our primary outcome (The Global health Status), and considering a correlation of 0.5 between inclusion and day 56 (corresponding in a standard deviation of the variation of the GHS score of 26 between baseline and day 56), and expecting a moderately clinically significant difference of 8 points between groups, it will be necessary to include 418 participants (bilateral test, alpha risk of 0.05, power of 0.8, attrition 0.2).

Considering the risk of lost to follow-up due to our population global condition, we considered an attrition rate of 20% when calculate the sample size.

Inclusion and non-inclusion criteria
Inclusion and non-inclusion criteria are summarized in Table 2.

There is no unanimous definition of advanced cancer. Scientific societies mainly agree to define advanced cancer as conditions that cannot be cured in the current state or science (Canadian cancer society, ESMO, [14]). However, they disagree with including the metastatic status (ESMO, [14]), impossibility to perform surgery (ESMO), or lack of response to first line treatments (CCS).

Based on these various definitions, in our study, we will rely on the following definition: “cancers that cannot be cured, and that, in the case of metastatic cancer, have usually spread from where they started to other parts of the body;” [15] in addition to “cancers that progress after a second line specific treatment or primary location of cancer that is unresectable”.

Patients will be considered to have a depressive syndrome if their Hospital Anxiety and Depression Scale-D score rates over 11(37), and if the clinical assessment supported by the results from the Montgomery and Åsberg Depression Rating Scale (38), confirm the diagnosis and the need for an antidepressant treatment.

Recruitment sites
Eleven French centers will handle recruitment. All centers have specialized palliative care services on site, including a palliative care unit. All of them take care of advanced cancer patients on a regular basis. The centers are seven University Hospitals, two Comprehensive Cancer Centers, one Public Hospital and one non-profit private hospital.

For practical justifications, the recruitment for the qualitative part of the study will be made only in one center. Centers are located in various French regions.

Study procedure
Recruitment and inclusion procedure
A screening for potential participants will be made by clinical teams in oncology or palliative care, during consultations, day hospital or conventional hospitalization. The principal investigator will be informed of every potential participant. He will verify inclusion and non-inclusion criteria. If the potential participant fulfills all requirements, the principal investigator will meet the patient to give information about the study (and about the qualitative part of it if needed).

Then the participant will be called at least 48 h after having received the oral and written information. They will be asked if they want to part to the study. If positive, an appointment for inclusion, randomization and baseline assessment will be booked. At inclusion, participants will sign an informed consent to participate. For those who will take part in the qualitative part, they will receive separate information and sign a specific consent form.

At inclusion, participants will be clinically examined with a postural hypotension test and an ECG if no prior ECG is available. If the participant does not have any non-inclusion criteria, he will be enrolled in the study and receive an anonymity code generated by the ENNOV Clinical software. Socio-demographic data will be collected. The participant will have to fulfil the EORTC QLQ-C30, Hospital Anxiety and Depression Scale – Depression (HADS-D), Edmonton Symptom Assessment Scale 12 French (ESAS-12F), and Antidepressive Side-Effect Checklist (ASEC) questionnaires. The principal investigator will fulfill the MADRS questionnaire and assess the patient’s Performance Status. If needed, the principal investigator will be able to ask for a psychiatric opinion.

Randomization
On the day on inclusion, participants will be randomly assigned to one of the two arms of the study by the ENNOV Clinical software. We will use the minimization method. Due to the important influence on quality of life, the Performance status, and the number of symptoms for which intensity is over 3 will be considered during randomization. The inclusion centre will also be considered.

Intervention and comparator
Mirtazapine will be compared to another antidepressant drug to avoid confusion bias in improving
health-related quality of life due to the lone antidepressant effect of mirtazapine. Escitalopram has been chosen as a comparator because it is, like mirtazapine, effective in treating depression in advanced cancer [16], with few medication interactions [17], but no effect on poly-symptomatology is expected.

Both drugs will be used following the usual practice for depression. They will be introduced at a low dose

| Table 2 Inclusion and non-inclusion criteria |
|---------------------------------------------|
| **Inclusion criteria**                      | **Non-inclusion criteria**                                                                 |
| Being over 18 years old                     | Being treated with an antidepressant agent during the four weeks before inclusion          |
| Suffering from an advanced cancer           | Having had a hypersensitivity event to mirtazapine, escitalopram of any excipient          |
| Having a clinically estimated life expectancy over 3 months | Having had a prior inefficient treatment with mirtazapine or escitalopram |
|                                             | Having postural hypotension or arterial systolic hypotension inferior to 90 mmHg measured following the guidelines of the European Society of Cardiology |
| Being diagnosed from having a depressive syndrome by a Hospital Anxiety and Depression Scale-D over 11 | Having a QT interval over 420 ms |
| Being in need of an antidepressant treatment | Having uncontrolled heart rhythm disorder or uncontrolled conduction disorder |
| Suffering from at least one under-controlled symptom (defined as a score over 3 on the Edmonton Symptom Assessment Scale) among: pain, nausea, vomiting, breathlessness, lack of appetite, sleep disorders, or anxiety | Having had or having bipolar disorder |
| Having or not a cancer treatment            | Having uncontrolled seizure or epilepsy (relative non-inclusion criteria needing a neurology specialist opinion) |
| Being able to understand the information related to the study, and to sign informed consent | Having or having a history of closed-angle glaucoma |
| Having agreed to take part in the study     | Having bone marrow aplasia |
|                                             | Practicing breastfeeding or being pregnant |
| Being able to fill Patient Reported Outcomes questionnaires | Women of childbearing age with no contraception method |
| Having genetic galactose intolerance or glucose-galactose malabsorption | Having a treatment with: |
| Being available to be called on days 7 and 14 | - Monoamine oxidase inhibitors (Selegiline, Moclobemide, Isocarboxazid, Nialamide, Phenelzine, Tranylcypromine, Iproniazid, Iproclozide, Toloxatone, Linezolid, Saffinamide, Rasagline) |
| Having hepatic failure                      | - One of the following antiarrhythmic drugs: Flecaïne, Propafenone, any class IA and III antiarrhythmic drug (amiodarone, disopyramide, hydroquinidine, quinidine, procainamide, sparteine, ajmaline, prajmaline, lorajmine, bretylium tosilate, bunaftine, doftelide, butilide, tedisamil, dronedarone) |
| Having a social security affiliation        | - Antipsychotic drugs (phenothiazine antipsychotics, pimozide, haloperidol) |
|                                               | - Linezolid, sparflexacin, moxifloxacin, macrolids (IV erythromycin, josamycin, clarithromycin, telithromycin), pentamidin, halofantrine, HIV protease inhibitors (ritonavir, nelfinavir, amprenavir, indinavir), azolic antifungal agents (ketoconazole, itraconazole, miconazole, fluconazole, voriconazole) |
| Having end-stage renal disease with a creatinine clearance inferior to 15 ml/min calculated using the Cockcroft's formula | - Mizolastine and Cimetidine |
| Having had hepatic failure                  | - Ticlopidine |
| Having a social security affiliation        | - Metoprolol |
|                                               | - Methadone |
|                                               | - Ketamine |
|                                               | - Triptan drugs |
|                                               | - Dapoxetine |
|                                               | - St. John’s wort |
|                                               | - Antidepressant drug |
|                                               | - Any other medication known to cause prolonged QT intervals |
| Having genetic galactose intolerance or glucose-galactose malabsorption | Having one of the following electrolyte disorders not corrected at the time of inclusion: hyponatremia, hyperkalemia, hypokalemia, hypermagnesemia, and hypomagnesemia |
| Having end-stage renal disease with a creatinine clearance inferior to 15 ml/min calculated using the Cockcroft's formula | Having hepatic failure |
| Having legal incapacity                      | Having hepatic failure |
regularly increase at day 7, 14 and 28 depending on the expected benefits from a higher dose and potential dose-dependent side effects. (Table 3).

**Follow-up procedure**

Follow-up will be made on a regular basis during a 56-day period.

Patients will be called by a research assistant on days 7 and 14 to screen for side effects using the ASEC scale. If any adverse event is screened a clinical opinion will be sought for dose adaptation based on predefined criteria. On day 14, escalation of dose will be prescribed by the PI if symptoms are still under controlled (the corresponding ESAS12-F subscale rated over 3) and in the absence of limiting side effect evaluated using the ASEC and Common Terminology Criteria for Adverse Events V4.0.

Clinical assessment will occur on day 28 (more or less 3 days). This assessment is meant to be made physically; however, if the patients’ condition of public-health situation demands it, it will be performed using teleconsultation. During this consultation, the patient will fulfil the EORTC QLQ-C30, ESAS -12F, HADS-D, ASEC, and factor 1 of the Medication Adherence Rating Scale (MARS) questionnaires. The PI will weigh the participant, count the number of pills that remains to the patient, evaluate the Performance Status and fill the MADRS.

**Outcomes assessment**

The outcomes will mainly be assessed using patients reported outcome measurements (PROMs) to better reflect the patients’ experience associated with the evaluated treatment. As depressive self-assessment of depressive state might not capture dynamic changes in depressive mood, the depressive mood assessment will rely on a self-assessment, a hetero-assessment and a composite criterion.

The primary outcome will be difference in the health related quality of life, measured at baseline and day 56 using the Global Health Status (GHS) score derived from the EORTC-QLQ-C30 [18–20]. We will consider that a small difference in the GHS score will be between 4 and 8, and a medium difference will be over 8 between baseline and day 56 [21, 22].

The secondary outcomes will include the improvement in the patient’s dynamic experience between baseline and day 56 of the negative experience of symptoms, explored using semi-structured interviews focusing on

---

**Table 3** Doses escalation during the study follow up

| Table 3 | Doses escalation during the study follow up |
|---------|--------------------------------------------|
|         | Starting doses – Day 0 | Day 7 | Day 14 | Day 28 |
|         | Mirtazapine: 15 mg | Escitalopram: 10 mg (or 5 mg for patients older than 65) | For patients under 65 in the escitalopram arm: decrease to 5 mg | For every other patients: Stop the treatment |
| Excessive drowsiness (CTCAE grade 1 or rated moderate or severe using the ASEC) | | | | |
| Any severe adverse effect or serious adverse event (CTCAE grade > 3 or rated severe using the ASEC) | | | | |
| Moderate adverse event (CTCAE grade 2 or rated moderate using the ASEC) | | | | |
| Mild adverse event (CTCAE grade 1 or rated mild using the ASEC) | | | | |
| No adverse event | Inadequate symptoms’ control (ESAS > 3) | | | |
| | Adequate symptoms’ control (ESAS ≤ 3) | | | |
the experience of symptoms, polymedication and taking antidepressant drugs.

The proportion of symptoms, for each patient, that have been reported as less intense using the ESAS-12F scale between baseline and day 56 if they were reported at baseline, among: depressive mood, pain, nausea, vomiting, loss of appetite, breathlessness, sleep disorders, and anxiety. A lesser degree of intensity will be considered from a 1 point difference [23].

The improvement in the intensity of each symptom using the ESAS-12F subscales between baseline, day 28 and day 56, if they were reported at baseline. A modification in the symptom’s intensity will be considered from a 1 point difference [23].

Any improvement in depressive mood will be assessed using the HADS-D scale and considering a modification in the patient’s mood from a 1.5 points difference between baseline, day 28 and day 56 [24]. We will also use a hetero evaluation scale, the Montgomery-Åsberg Depression Ratting Scale (MADRS) to compare depressive mood between baseline, day 28 and day 56. A difference over 1.9 points will be considered as significant [25]. A composite criterion of both scales’ improvement will also be assessed between baseline, day 28 and day 56 [24, 25].

The proportion of patients having an improvement in the different EORCT-QLQ-C30 functioning scales will be compared between baseline, day 28 and day 56. The following cut-offs will be used for defining significant changes: 3 points for the Cognitive Functioning, 2 points for the Physical functioning, and 6 points for the Emotional Functioning and Role functioning [26, 27]. Financial functioning will not be assessed as the French health care system does not fit with this evaluation (cancer care is free of charge to the patient).

Weight variations will be assessed between baseline, day 28 and day 56.

The use of painkillers will be assessed using the proportion of patients that had stable (±20%) morphine oral equivalent between baseline, day 28 and day 56. For other symptomatic treatments, the proportion of patients that increased the doses (or had new symptomatic treatment) between baseline, day 28 and day 56 will be assessed.

The security of use will be assessed using the number of new adverse effects reported using the ASEC clinical trials under the French law.

No data monitoring committee will set up. The sponsor will handle data monitoring twice a year for the time of the study and following the French legal requirements.

The study design complies with the Consolidated Standards of Reporting Trials (CONSORT) statement, and the current protocol complies with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) [31].

Discussion
If mirtazapine is proven to be efficient in improving patients’ quality of life, independently of its antidepressant effect, in advanced cancer poly-symptomatic
patients would constitute a major progress. Additionally, this study might highlight target symptoms that could be relieved using mirtazapine and potential target symptom clusters.

This could allow limiting polypharmacy in advanced cancer patients by offering a new therapeutic option well tolerated in this frail population. Additionally, this would mitigate the risk of adverse event and drugs interaction in this population often affected by polypharmacy due to numerous conditions and symptoms. This would constitute a major step for patients’ security. As mirtazapine is a very cheap drug, this would also contribute in limiting health care expenditures.

Besides limiting polypharmacy, several symptoms have very limited therapeutic options currently available. This is the case for cancer anorexia. Few drugs, including megestrol acetate and corticoids, have been proven to be effective in improving appetite. However, they have important side effects, limiting their use in the overall advanced cancer population. As mirtazapine is expected to be well tolerated, any effectiveness in improving appetite might open an interesting therapeutic way for anorexia in advanced cancer.

For breathlessness treatment, no drug is currently licensed in the European Union. Morphine has been evaluated many times, but its effectiveness is still under debate. King’s College London recently launched an ambitious project aiming to assess the effectiveness of mirtazapine in alleviating breathlessness in chronic lung disease [32]. Results from this wide UK randomized controlled trial and form our study could motivate considering licensing mirtazapine in treating this symptom.

Additionally, mirtazapine is available in many countries under the shape of orodispersible tablets. This galenic form ensures its use for most cancer patients, including those who have swallowing disorders, intestinal obstruction or any other contraindication for oral intakes, while limiting venous access when not necessary.

Beyond the potential benefits to the patients and public health this study will inform further researches by providing information on advanced cancer patients’ quality of life, their experience of polysymptomatology and polypharmacy. This will also provide information on further researches on mirtazapine. Finally, feedback from this mixed-method randomized-controlled trial will provide useful information to subjective and objective aspects of research in palliative care patients’ quality of life, and thereafter suggests future methodological improvements.

Limitations
For practical reasons, the current trial will be an open-trial. A recent modification in grading the evidence does not inevitably consider open-labeled trials as subject to important biases. Despite this new grading system, a blinded trial would have probably provided better evidence. To avoid biases, analyses, including qualitative analyses, will be performed by blinded researchers [33]. In this purpose, the researcher that will transcribe the semi-structured interviews verbatim will remove any identifiable data in the verbatim and blind them for randomization arm. This researcher will not take part in qualitative analyses.

Abbreviations
ADEC: Antidepressant Side-Effect Checklist; CCS: Canadian Cancer Society; CTCAE V4.0 / CTCAE: Common Terminology Criteria for Adverse Events Fourth Version; ECG: Electrocardiogram; EORTC QLQ-C30 / QLQ-C30: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30; ESAS 12F: Edmonton Symptom Assessment Scale 12 French; ESMO: European Society for Medical Oncology; GHS: Global Health Status; HRQoL: Health-Related Quality of life; MADRS: Montgomery-Åsberg Depression Rating Scale; HADS-D: Hospital Anxiety and Depression Scale—Depression; MARS: Medication Adherence Report Scale.

Acknowledgements
We would like to thank the members of the methodological committee of the Hospices Civils de Lyon that made valuable remarks on the protocol.

Authors’ contributions
All authors read and approved the current manuscript. GE: Designed the whole project, wrote the study’s protocol. MA: Has a significant impact on administrative duty management, handled legal requirements, reviewed the protocol, and approved its final version. LV: Has a significant impact on administrative duty management, handled legal requirements, reviewed the protocol, and approved its final version. EP: Coordinates the clinical side of this study, she reviewed the protocol, and approved its final version. FS: Has reviewed the protocol, developed the statistical analysis plan, and approved its final version. JH: Co-coordinated the project development, methodologically reviewed the protocol (for the quantitative section), and approved its final version. OG: Co-coordinated the project development, reviewed the protocol, and approved its final version.

Funding
This trial received 213 000 euros from the Interregional call for Hospital Programs of Clinical Research (PHRCl: Programme Hospitalier de Recherche Clinique—Interrégional), granted by the French General Direction of Healthcare Offer (DGOS: Direction Générale de l’Offre de Soins) – French ministry of Health. The funder is French national public body that mandated experts to fully peer-review the protocol, approved the protocol, supports the costs issued from the study to the maximum amount of 213 000 euros and will follow the study enrollment rate and final result. It has no competing interest in the medication tested in the study. The funding body reviewed the protocol. They will not interfere with the data collection, data analysis or interpretation.

Availability of data and materials
The current protocol is labeled by the number NCT04763135 on ClinicalTrials.gov. The current protocol is labeled by the number 2020–002,994–90 on the European Union Drug Regulating Authorities Clinical Trials Database.

Declarations
Ethics approval and consent to participate
The study protocol and consent form have been approved on the 07/12/2020 by the Committee for Persons Protection Sud Est I (CPP – Comité de Protection des Personnes). The decision has been labeled by the approval number MEDAE CPP-2020–10-00020.
All participant will receive appropriate information and will be requested to give written informed consent for participating in the study.

Consent for publication
Not applicable.

Competing Interests
The authors declare that they have no competing interests.

Author details
1. EA 3738 - CCILy - Centre d’Innovation en Cancérologie de Lyon, UFR Faculté de Médecin Lyon-Sud-Charles Mériaux BP1, Université Claude Bernard Lyon 1, 165, Chemin du Grand Revoyet, 69921 Oullins Cedex, France.
2. Palliative Care Center, Hospices Civils de Lyon, 165, Chemin du Grand Revoyet, 69495 Pierre-Bénite, France.
3. Public Health, Research and Clinical Epidemiology, Hospices Civils de Lyon, 165, Chemin du Grand Revoyet, 69495 Pierre-Bénite, France.
4. Surgical Oncology, Hospices Civils de Lyon, 165, Chemin du Grand Revoyet, 69495 Pierre-Bénite, France.

Received: 23 April 2021 Accepted: 11 May 2022
Published online: 23 May 2022

References
1. Haun MW, Estel S, Rücker G, Friederich H-C, Villalobos M, Thomas M, et al. Early palliative care for adults with advanced cancer: Cochrane Pain, Palliative and Supportive Care Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2017 Jun 12 [cited 2019 Feb 21]; Available from: https://doi.org/10.1002/14651858.CD011129.pub2
2. Jordan K, Aapro M, Kaasa S, Ripamonti C, Scotté F, Strasser F, et al. European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol. 2018;29(1):86–43.
3. Cheung WY, Le LW, Zimmermann C. Symptom clusters in patients with advanced cancers: Support Care Cancer. 2009;17(9):1223–30.
4. Teunissen S, Wefers W, Kroftvagen C, de Haes H, Cichon E, van Eeghem A. Symptom Prevalence in Patients with Incurable Cancer: A Systematic Review. J Pain Symptom Manage. 2007;34(1):94–104.
5. Kierner KA, Weidler D, Masel EK, Gartner V, Watzke HH. Polypharmacy in the terminal stage of cancer. Support Care Cancer. 2016;24(25):2067–74.
6. Nightingale G, Skonecki E, Boparai MK. The Impact of Polypharmacy on Patient Outcomes in Older Adults With Cancer. Cancer J. 2017;23(4):211–8.
7. Carvalho AF, Sharma MS, Brunoni AR, Viera E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressants: A Critical Review of the Literature. Psychother Psychosom. 2016;85(5):270–88.
8. Lovell N, Ward J. The role of mirtazapine in treating multiple symptoms in patients with cancer. Clinical Focus Cancer Medicine. 2011;1(2):61–4.
9. Amttia SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64.
10. Cankurtaran ES, Ozalp E, Seryozhuk A, Akbiyik DI, Turhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer. 2008;16(1):1291–8.
11. Lovell N, Wilcock A, Bavjah S, Etkind SN, Jolley CJ, Maddocks M, et al. Mirtazapine for chronic breathlessness? A review of mechanistic insights and therapeutic potential. Expert Rev Respir Med. 2019;13(2):173–80.
12. Riegelmann RR, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia [Erratum appears in Am J Hospice Palliative Med. 2010;27(2):106–10].
13. Economos G, Lovell N, Johnston A, Higginson IJ. What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review Support Care Cancer. 2020;28(4):597–606.
14. Understanding Advanced Cancer, Metastatic Cancer, and Bone Metastasis [Internet]. [cited 2020 Aug 7]; Available from: https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/what-is.html
15. Haun MW, Estel S, Rücker G, Friederich H-C, Villalobos M, Thomas M, et al. Early palliative care for adults with advanced cancer. Cochrane Pain, Palliative and Supportive Care Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2017 Jun 12 [cited 2020 Aug 7]; Available from: https://doi.org/10.1002/14651858.CD011129.pub2
16. Ostuzzi G, Matcham F, Dauchy S, Baruc B, Hopot M. Antidepressants for the treatment of depression in people with cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database of Systematic Reviews [Internet]. 2018 Apr 23 [cited 2019 Feb 27]; Available from: https://doi.org/10.1002/14651858.CD011006.pub3
17. Hirschfeld RA, Vornik LA. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry. 2004;65(Suppl 4):46–52.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI J National Cancer Institute. 1993;85(5):365–76.
19. Coates A, Porzelt F, Osoba D. Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33(7):1025–30.
20. Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol. 1997;50(4):441–50.
21. Cocks K, King MT, Velikova G, de Castro G, Martyn St-James M, Fayers PM, et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48(11):1713–21.
22. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29(11):89–96.
23. Hui D, Sharmie O, Paiva CE, Perez-Cruz PE, Kwon JH, Muckaden MA, et al. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: A prospective, multicenter study: Symptom Response Determination. Cancer. 2015;121(17):3027–32.
24. Puhan MA, Frey M, Büchi S, Schumemann H. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6(6):46.
25. Duru G, Fattino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24(5):1329–35.
26. on behalf of the EORTC PROBE, Maringwa JT, Quinnet C, King M, Ringash J, Osoba D, et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer. 2011;19(11):1753–60.
27. Zeng L, Chow E, Zhang L, Tseng L-M, Hou M-F, Fairchild A, et al. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Support Care Cancer. 2012;20(12):3307–13.
28. Raebl MA, Schmittfeld J, Karter AJ, Konieczny JL, Steiner JF. Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases. Med Care. 2013;51:511-21.
29. Leppert W, Zdun-Ryzewska A, Foryczka M, Mess E, Majkowski M. Quality of life assessment in advanced cancer patients treated at home, an inpatient unit, and a day care center. Onco Targets Ther. 2014;7:687–95.
30. Jordhøy MS, Fayers P, Loge JH, Saltnes T, Ahnner-Elmqvist M, Kaasa S. Quality of life in advanced cancer patients: the impact of sociodemographic and medical characteristics. Br J Cancer. 2001;85(10):1476–85.
31. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med. 2013;158(3):200.
32. Cook H. Better treatments for refractory breathlessness [Internet]. ISRCTN; [cited 2021 Feb 19]; Available from: http://www.isrctn.org/ISRCTN82231610
33. Kahan BC, Cro S, Doré CJ, Bratton DJ, Rehal S, Maskell NA, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;15(1):456.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.